Who are Celebrex, acetaminophen, and dexamethasone's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/celebrex-acetaminophen-and-dexamethasone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Celebrex, acetaminophen, and dexamethasone — Competitive Intelligence Brief

Celebrex, acetaminophen, and dexamethasone (Celebrex, acetaminophen, and dexamethasone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination analgesic and anti-inflammatory. Area: Pain Management, Rheumatology, Inflammation.

phase 3 Combination analgesic and anti-inflammatory COX-2, TRPV1 (acetaminophen), glucocorticoid receptor Pain Management, Rheumatology, Inflammation Small molecule Live · refreshed every 30 min

Target snapshot

Celebrex, acetaminophen, and dexamethasone (Celebrex, acetaminophen, and dexamethasone) — Gangnam Severance Hospital. This combination reduces pain and inflammation through COX inhibition (Celebrex), blocks pain signal transmission (acetaminophen), and suppresses immune-mediated inflammation (dexamethasone).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Celebrex, acetaminophen, and dexamethasone TARGET	Celebrex, acetaminophen, and dexamethasone	Gangnam Severance Hospital	phase 3	Combination analgesic and anti-inflammatory	COX-2, TRPV1 (acetaminophen), glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination analgesic and anti-inflammatory class)

Gangnam Severance Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Celebrex, acetaminophen, and dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/celebrex-acetaminophen-and-dexamethasone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab